Moskwa P S, Vadi H, Drewinko B
Cancer Res. 1985 Nov;45(11 Pt 1):5447-51.
Three established human colon carcinoma cell lines (LoVo, SW620, and SW403) with different degrees of phenotype differentiation were investigated for their sensitivity to the cytotoxic effects of cyclophosphamide (CP) and to its active metabolite, 4-hydroxycyclophosphamide (4-OH-CP), and for their mixed function oxidase (MFO) activities. None of the cell lines showed sensitivity to CP as determined by the inhibition of colony formation assay, even after continuous drug treatment at high concentrations (200 microgram/ml) for up to 72 h. CP also had no effect on the cellular doubling time or on the incorporation of [3H]-thymidine. Pretreatment with phenobarbital (PB) plus hydrocortisone (HC) was unable to induce CP cytotoxicity. In contrast, 4-OH-CP, the major metabolite formed from CP by MFO, was highly toxic to the cells. About 90% cell kill was obtained at drug concentrations of 17.5 microgram/ml (LoVo), 15 microgram/ml (SW620), and 55 microgram/ml (SW403) after 1-h incubation at 37 degrees. MFO activities were determined by measuring p-nitroanisole demethylase (PNAD) and arylhydrocarbon hydroxylase (AHH) in microsomes prepared from noninduced cells or from cells treated with benzanthracene or PB plus HC. Intrinsic AHH activities were below the level of detection for all cell lines [less than 1 pmol of 3-hydroxybenzo(a)pyrene (3-OH-BP) formed per min per mg of protein]. Treatment with benzanthracene resulted in AHH activities of 12 to 15 pmol of 3-OH-BP per min per mg of protein, but treatment with PB plus HC failed to induce significant AHH activities. PNAD activities in noninduced cells as well as in cells treated with benzanthracene were 0.05 to 0.08 nmol of p-nitrophenol formed per min per mg of protein; treatment with PB plus HC increased PNAD activities by only 1.5-fold. Thus, in contrast to reports for rat colon and for a single human colon cancer cell line, CP is inactive when applied directly to several other human colon carcinoma cell lines. Because these cells have minimally detectable intrinsic and induced MFO activities, we conclude that CP cannot be successfully metabolized into 4-OH-CP to induce a significant degree of cell kill.
研究了三种具有不同程度表型分化的成熟人结肠癌细胞系(LoVo、SW620和SW403)对环磷酰胺(CP)及其活性代谢物4-羟基环磷酰胺(4-OH-CP)细胞毒性作用的敏感性以及它们的混合功能氧化酶(MFO)活性。通过集落形成试验抑制法测定,即使在高浓度(200微克/毫升)连续药物处理长达72小时后,这些细胞系中没有一个显示出对CP的敏感性。CP对细胞倍增时间或[3H] - 胸腺嘧啶掺入也没有影响。用苯巴比妥(PB)加氢皮质激素(HC)预处理无法诱导CP的细胞毒性。相比之下,由MFO将CP转化形成的主要代谢物4-OH-CP对细胞具有高度毒性。在37℃孵育1小时后,药物浓度为17.5微克/毫升(LoVo)、15微克/毫升(SW620)和55微克/毫升(SW403)时可导致约90%的细胞死亡。通过测量从未诱导细胞或用苯并蒽或PB加HC处理的细胞制备的微粒体中的对硝基苯甲醚脱甲基酶(PNAD)和芳烃羟化酶(AHH)来测定MFO活性。所有细胞系的内在AHH活性均低于检测水平[每分钟每毫克蛋白质形成的3-羟基苯并(a)芘(3-OH-BP)少于1皮摩尔]。用苯并蒽处理导致AHH活性为每分钟每毫克蛋白质12至15皮摩尔的3-OH-BP,但用PB加HC处理未能诱导出显著的AHH活性。未诱导细胞以及用苯并蒽处理的细胞中的PNAD活性为每分钟每毫克蛋白质形成0.05至0.08纳摩尔的对硝基苯酚;用PB加HC处理仅使PNAD活性增加了1.5倍。因此,与关于大鼠结肠和单一人类结肠癌细胞系的报道相反,当直接应用于其他几种人类结肠癌细胞系时,CP没有活性。由于这些细胞的内在和诱导的MFO活性极低,我们得出结论,CP不能成功代谢为4-OH-CP以诱导显著程度的细胞死亡。